BLI Banque de Luxembourg Investments Sells 14,052 Shares of IDEXX Laboratories, Inc. $IDXX

BLI Banque de Luxembourg Investments cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 55,771 shares of the company’s stock after selling 14,052 shares during the period. IDEXX Laboratories comprises approximately 1.1% of BLI Banque de Luxembourg Investments’ holdings, making the stock its 26th largest position. BLI Banque de Luxembourg Investments’ holdings in IDEXX Laboratories were worth $38,041,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in IDXX. Virtus Advisers LLC bought a new position in shares of IDEXX Laboratories in the 3rd quarter worth about $26,000. Park Place Capital Corp bought a new position in shares of IDEXX Laboratories in the 4th quarter worth about $29,000. WealthCollab LLC bought a new position in shares of IDEXX Laboratories in the 2nd quarter worth about $30,000. Caitong International Asset Management Co. Ltd bought a new position in shares of IDEXX Laboratories in the 3rd quarter worth about $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC raised its position in shares of IDEXX Laboratories by 58.8% in the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after acquiring an additional 20 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $561.17 on Tuesday. IDEXX Laboratories, Inc. has a twelve month low of $506.91 and a twelve month high of $769.98. The stock’s 50 day moving average price is $562.81 and its 200-day moving average price is $631.11. The company has a market capitalization of $44.27 billion, a PE ratio of 41.32, a PEG ratio of 3.08 and a beta of 1.56. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on IDXX shares. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Piper Sandler reduced their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. UBS Group reduced their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Finally, Citigroup started coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price for the company. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.